{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:25:57Z","timestamp":1781101557829,"version":"3.54.1"},"reference-count":65,"publisher":"National Academy of Sciences","issue":"30","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-OD011095"],"award-info":[{"award-number":["R01-OD011095"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI028433"],"award-info":[{"award-number":["R01-AI028433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI078881"],"award-info":[{"award-number":["R01-AI078881"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI116868"],"award-info":[{"award-number":["R01-AI116868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI088791"],"award-info":[{"award-number":["U19 AI088791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI45008"],"award-info":[{"award-number":["P30 AI45008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["DE-AC52-06NA25396"],"award-info":[{"award-number":["DE-AC52-06NA25396"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,7,24]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Viral populations exhibit an extraordinary ability to survive abrupt changes in host environment by rapidly generating adaptive mutations. However, our understanding of how viral populations respond to selection pressure and the underlying molecular mechanisms supporting viral adaptation in vivo is limited. Here, we report a set of clinical data sampled from subjects chronically infected by hepatitis C virus (HCV). The data show rapid expansion and turnover of drug-resistant viruses following treatment with an HCV protease inhibitor. By fitting mathematical models to the data, we propose that superinfection and cure of infected cells play critical roles in facilitating the rapid expansion and turnover of viral populations. Our results highlight the importance of considering intracellular viral competition in understanding rapid viral adaptation.<\/jats:p>","DOI":"10.1073\/pnas.1805267115","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T15:17:33Z","timestamp":1531149453000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":17,"title":["Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence"],"prefix":"10.1073","volume":"115","author":[{"given":"Ruian","family":"Ke","sequence":"first","affiliation":[{"name":"Department of Mathematics, North Carolina State University, Raleigh, NC 27695;"},{"name":"Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104;"},{"name":"Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104;"},{"name":"Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104;"},{"name":"Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-8241","authenticated-orcid":false,"given":"Ruy M.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545;"},{"name":"Laboratory of Biomathematics, Faculty of Medicine, University of Lisbon, 1600-276 Lisbon, Portugal;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-652X","authenticated-orcid":false,"given":"Tanmoy","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545;"},{"name":"Santa Fe Institute, Santa Fe, NM 87501;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J. O.","family":"Barnard","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Merck &amp; Co., Inc., Kenilworth, NJ 07033"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice H.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104;"},{"name":"Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104;"},{"name":"Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[{"name":"Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545;"},{"name":"Santa Fe Institute, Santa Fe, NM 87501;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo E","year":"2012","unstructured":"E Domingo, J Sheldon, C Perales, Viral quasispecies evolution. Microbiol Mol Biol Rev 76, 159\u2013216 (2012).","journal-title":"Microbiol Mol Biol Rev"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrmicro3003","article-title":"The role of mutational robustness in RNA virus evolution","volume":"11","author":"Lauring AS","year":"2013","unstructured":"AS Lauring, J Frydman, R Andino, The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol 11, 327\u2013336 (2013).","journal-title":"Nat Rev Microbiol"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei X","year":"2003","unstructured":"X Wei, , Antibody neutralization and escape by HIV-1. Nature 422, 307\u2013312 (2003).","journal-title":"Nature"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1074-7613(01)00245-X","article-title":"The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes","volume":"15","author":"Erickson AL","year":"2001","unstructured":"AL Erickson, , The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883\u2013895 (2001).","journal-title":"Immunity"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong L","year":"2010","unstructured":"L Rong, H Dahari, RM Ribeiro, AS Perelson, Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2, 30ra32 (2010).","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"Rosenbloom DI","year":"2012","unstructured":"DI Rosenbloom, AL Hill, SA Rabi, RF Siliciano, MA Nowak, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 18, 1378\u20131385 (2012).","journal-title":"Nat Med"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele BF","year":"2008","unstructured":"BF Keele, , Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105, 7552\u20137557 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"e1000745","DOI":"10.1371\/journal.pcbi.1000745","article-title":"A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants","volume":"6","author":"Adiwijaya BS","year":"2010","unstructured":"BS Adiwijaya, , A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 6, e1000745 (2010).","journal-title":"PLoS Comput Biol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations","volume":"54","author":"Fridell RA","year":"2011","unstructured":"RA Fridell, , Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations. Hepatology 54, 1924\u20131935 (2011).","journal-title":"Hepatology"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/jac\/dkt423","article-title":"Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration","volume":"69","author":"Ke R","year":"2014","unstructured":"R Ke, , Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69, 724\u2013727 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1128\/JVI.74.11.5257-5265.2000","article-title":"Low dynamic state of viral competition in a chronic avian hepadnavirus infection","volume":"74","author":"Zhang YY","year":"2000","unstructured":"YY Zhang, J Summers, Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 74, 5257\u20135265 (2000).","journal-title":"J Virol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"e1004040","DOI":"10.1371\/journal.pcbi.1004040","article-title":"Rational design and adaptive management of combination therapies for hepatitis C virus infection","volume":"11","author":"Ke R","year":"2015","unstructured":"R Ke, C Loverdo, H Qi, R Sun, JO Lloyd-Smith, Rational design and adaptive management of combination therapies for hepatitis C virus infection. PLoS Comput Biol 11, e1004040 (2015).","journal-title":"PLoS Comput Biol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.epidem.2012.10.001","article-title":"Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics","volume":"4","author":"Alexander HK","year":"2012","unstructured":"HK Alexander, S Bonhoeffer, Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics. Epidemics 4, 187\u2013202 (2012).","journal-title":"Epidemics"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2893.2010.01348.x","article-title":"A perspective on modelling hepatitis C virus infection","volume":"17","author":"Guedj J","year":"2010","unstructured":"J Guedj, L Rong, H Dahari, AS Perelson, A perspective on modelling hepatitis C virus infection. J Viral Hepat 17, 825\u2013833 (2010).","journal-title":"J Viral Hepat"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"20120150","DOI":"10.1098\/rstb.2012.0150","article-title":"Vacated niches, competitive release and the community ecology of pathogen eradication","volume":"368","author":"Lloyd-Smith JO","year":"2013","unstructured":"JO Lloyd-Smith, Vacated niches, competitive release and the community ecology of pathogen eradication. Philos Trans R Soc Lond B Biol Sci 368, 20120150 (2013).","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1098\/rspb.1997.0089","article-title":"Pre-existence and emergence of drug resistance in HIV-1 infection","volume":"264","author":"Bonhoeffer S","year":"1997","unstructured":"S Bonhoeffer, MA Nowak, Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Biol Sci 264, 631\u2013637 (1997).","journal-title":"Proc Biol Sci"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1073\/pnas.0603626104","article-title":"The role of cells refractory to productive infection in acute hepatitis B viral dynamics","volume":"104","author":"Ciupe SM","year":"2007","unstructured":"SM Ciupe, RM Ribeiro, PW Nelson, G Dusheiko, AS Perelson, The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci USA 104, 5050\u20135055 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1137\/S0036144598335107","article-title":"Mathematical analysis of HIV-1 dynamics in vivo","volume":"41","author":"Perelson AS","year":"1999","unstructured":"AS Perelson, PW Nelson, Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev 41, 3\u201344 (1999).","journal-title":"SIAM Rev"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.3184","article-title":"Global control of hepatitis C: Where challenge meets opportunity","volume":"19","author":"Thomas DL","year":"2013","unstructured":"DL Thomas, Global control of hepatitis C: Where challenge meets opportunity. Nat Med 19, 850\u2013858 (2013).","journal-title":"Nat Med"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld JJ","year":"2015","unstructured":"JJ Feld, , Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med; ASTRAL-1 Investigators 373, 2599\u20132607 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","article-title":"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: A phase 2, open-label, proof-of-concept study","volume":"1","author":"Lau G","year":"2016","unstructured":"G Lau, , Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: A phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 1, 97\u2013104 (2016).","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial","volume":"385","author":"Sulkowski M","year":"2015","unstructured":"M Sulkowski, , Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial. Lancet 385, 1087\u20131097 (2015).","journal-title":"Lancet"},{"key":"e_1_3_4_23_2","first-page":"706A","article-title":"Safety and antiviral activity of MK-5172, a novel HCV NS3\/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients","volume":"52","author":"Brainard DM","year":"2010","unstructured":"DM Brainard, , Safety and antiviral activity of MK-5172, a novel HCV NS3\/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52, 706A\u2013707A (2010).","journal-title":"Hepatology"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe AY","year":"2014","unstructured":"AY Howe, , Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis 59, 1657\u20131665 (2014).","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami T","year":"2011","unstructured":"T Shimakami, , Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140, 667\u2013675 (2011).","journal-title":"Gastroenterology"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa V","year":"2012","unstructured":"V Summa, , MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56, 4161\u20134167, and erratum (2014) 58:4995 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1126\/science.1090727","article-title":"Unifying the epidemiological and evolutionary dynamics of pathogens","volume":"303","author":"Grenfell BT","year":"2004","unstructured":"BT Grenfell, , Unifying the epidemiological and evolutionary dynamics of pathogens. Science 303, 327\u2013332 (2004).","journal-title":"Science"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: Estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro RM","year":"2012","unstructured":"RM Ribeiro, , Quantifying the diversification of hepatitis C virus (HCV) during primary infection: Estimates of the in vivo mutation rate. PLoS Pathog 8, e1002881 (2012).","journal-title":"PLoS Pathog"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann AU","year":"1998","unstructured":"AU Neumann, , Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103\u2013107 (1998).","journal-title":"Science"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"Snoeck E","year":"2010","unstructured":"E Snoeck, , A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87, 706\u2013713 (2010).","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj J","year":"2013","unstructured":"J Guedj, , Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 110, 3991\u20133996 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration","volume":"53","author":"Guedj J","year":"2011","unstructured":"J Guedj, AS Perelson, Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration. Hepatology 53, 1801\u20131808 (2011).","journal-title":"Hepatology"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"Blight KJ","year":"2002","unstructured":"KJ Blight, JA McKeating, CM Rice, Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76, 13001\u201313014 (2002).","journal-title":"J Virol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","article-title":"Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells","volume":"48","author":"Lin K","year":"2004","unstructured":"K Lin, AD Kwong, C Lin, Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 48, 4784\u20134792 (2004).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1128\/JVI.77.5.3007-3019.2003","article-title":"Viral and cellular determinants of hepatitis C virus RNA replication in cell culture","volume":"77","author":"Lohmann V","year":"2003","unstructured":"V Lohmann, S Hoffmann, U Herian, F Penin, R Bartenschlager, Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 77, 3007\u20133019 (2003).","journal-title":"J Virol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1073\/pnas.0235524100","article-title":"Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs","volume":"100","author":"Randall G","year":"2003","unstructured":"G Randall, A Grakoui, CM Rice, Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 100, 235\u2013240 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2015.05.011","article-title":"In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying\/preventing the development of drug resistance","volume":"120","author":"Vliegen I","year":"2015","unstructured":"I Vliegen, J Paeshuyse, W Zhong, J Neyts, In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying\/preventing the development of drug resistance. Antiviral Res 120, 112\u2013121 (2015).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jtbi.2010.08.036","article-title":"Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics","volume":"267","author":"Guedj J","year":"2010","unstructured":"J Guedj, AU Neumann, Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 267, 330\u2013340 (2010).","journal-title":"J Theor Biol"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.02144-06","article-title":"Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes","volume":"81","author":"Schaller T","year":"2007","unstructured":"T Schaller, , Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol 81, 4591\u20134603 (2007).","journal-title":"J Virol"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1128\/JVI.01748-06","article-title":"Superinfection exclusion in cells infected with hepatitis C virus","volume":"81","author":"Tscherne DM","year":"2007","unstructured":"DM Tscherne, , Superinfection exclusion in cells infected with hepatitis C virus. J Virol 81, 3693\u20133703 (2007).","journal-title":"J Virol"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1128\/JVI.02465-13","article-title":"Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus","volume":"87","author":"Webster B","year":"2013","unstructured":"B Webster, M Ott, WC Greene, Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J Virol 87, 13354\u201313369 (2013).","journal-title":"J Virol"},{"key":"e_1_3_4_42_2","volume-title":"Ecological Models and Data in R","author":"Bolker BM","year":"2008","unstructured":"BM Bolker Ecological Models and Data in R (Princeton Univ Press, Princeton, 2008)."},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1534\/genetics.106.067678","article-title":"Beneficial mutation selection balance and the effect of linkage on positive selection","volume":"176","author":"Desai MM","year":"2007","unstructured":"MM Desai, DS Fisher, Beneficial mutation selection balance and the effect of linkage on positive selection. Genetics 176, 1759\u20131798 (2007).","journal-title":"Genetics"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1017067816551","article-title":"The fate of competing beneficial mutations in an asexual population","volume":"102","author":"Gerrish PJ","year":"1998","unstructured":"PJ Gerrish, RE Lenski, The fate of competing beneficial mutations in an asexual population. Genetica 102-103, 127\u2013144 (1998).","journal-title":"Genetica"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"e1002959","DOI":"10.1371\/journal.pcbi.1002959","article-title":"Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model","volume":"9","author":"Rong L","year":"2013","unstructured":"L Rong, , Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol 9, e1002959 (2013).","journal-title":"PLoS Comput Biol"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hep.27361","article-title":"Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir\/ribavirin","volume":"61","author":"Hedskog C","year":"2015","unstructured":"C Hedskog, , Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir\/ribavirin. Hepatology 61, 471\u2013480 (2015).","journal-title":"Hepatology"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JCM.00483-15","article-title":"Characterization of hepatitis C virus recombination in Cameroon by use of nonspecific next-generation sequencing","volume":"53","author":"Iles JC","year":"2015","unstructured":"JC Iles, , Characterization of hepatitis C virus recombination in Cameroon by use of nonspecific next-generation sequencing. J Clin Microbiol 53, 3155\u20133164 (2015).","journal-title":"J Clin Microbiol"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2893.2010.01367.x","article-title":"Genetic recombination of the hepatitis C virus: Clinical implications","volume":"18","author":"Morel V","year":"2011","unstructured":"V Morel, , Genetic recombination of the hepatitis C virus: Clinical implications. J Viral Hepat 18, 77\u201383 (2011).","journal-title":"J Viral Hepat"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/JVI.06184-11","article-title":"Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k\/1b","volume":"86","author":"Raghwani J","year":"2012","unstructured":"J Raghwani, , Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k\/1b. J Virol 86, 2212\u20132220 (2012).","journal-title":"J Virol"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"e1002880","DOI":"10.1371\/journal.ppat.1002880","article-title":"Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing","volume":"8","author":"Li H","year":"2012","unstructured":"H Li, , Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog 8, e1002880 (2012).","journal-title":"PLoS Pathog"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"e02518","DOI":"10.1128\/mBio.02518-14","article-title":"Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted\/founder genotypes 1, 3, and 4","volume":"6","author":"Stoddard MB","year":"2015","unstructured":"MB Stoddard, , Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted\/founder genotypes 1, 3, and 4. MBio 6, e02518 (2015).","journal-title":"MBio"},{"key":"e_1_3_4_52_2","doi-asserted-by":"crossref","first-page":"e1003934","DOI":"10.1371\/journal.pcbi.1003934","article-title":"Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes","volume":"10","author":"Graw F","year":"2014","unstructured":"F Graw, , Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Comput Biol 10, e1003934 (2014).","journal-title":"PLoS Comput Biol"},{"key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1128\/JVI.00016-15","article-title":"Quantification of hepatitis C virus cell-to-cell spread using a stochastic modeling approach","volume":"89","author":"Graw F","year":"2015","unstructured":"F Graw, DN Martin, AS Perelson, SL Uprichard, H Dahari, Quantification of hepatitis C virus cell-to-cell spread using a stochastic modeling approach. J Virol 89, 6551\u20136561 (2015).","journal-title":"J Virol"},{"key":"e_1_3_4_54_2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1053\/j.gastro.2013.08.034","article-title":"Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver","volume":"145","author":"Kandathil AJ","year":"2013","unstructured":"AJ Kandathil, , Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 145, 1404\u20131413.e10 (2013).","journal-title":"Gastroenterology"},{"key":"e_1_3_4_55_2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/hep.26770","article-title":"Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver","volume":"59","author":"Wieland S","year":"2014","unstructured":"S Wieland, , Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59, 2121\u20132130 (2014).","journal-title":"Hepatology"},{"key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1098\/rspb.1995.0138","article-title":"Coinfection and the evolution of parasite virulence","volume":"261","author":"May RM","year":"1995","unstructured":"RM May, MA Nowak, Coinfection and the evolution of parasite virulence. Proc Biol Sci 261, 209\u2013215 (1995).","journal-title":"Proc Biol Sci"},{"key":"e_1_3_4_57_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1098\/rspb.1994.0012","article-title":"Superinfection and the evolution of parasite virulence","volume":"255","author":"Nowak MA","year":"1994","unstructured":"MA Nowak, RM May, Superinfection and the evolution of parasite virulence. Proc Biol Sci 255, 81\u201389 (1994).","journal-title":"Proc Biol Sci"},{"key":"e_1_3_4_58_2","doi-asserted-by":"crossref","first-page":"92872","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey JR","year":"2017","unstructured":"JR Bailey, , Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight 2, 92872 (2017).","journal-title":"JCI Insight"},{"key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev-virology-110615-042249","article-title":"Modeling viral spread","volume":"3","author":"Graw F","year":"2016","unstructured":"F Graw, AS Perelson, Modeling viral spread. Annu Rev Virol 3, 555\u2013572 (2016).","journal-title":"Annu Rev Virol"},{"key":"e_1_3_4_60_2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1128\/JVI.03306-14","article-title":"Influenza A virus uses intercellular connections to spread to neighboring cells","volume":"89","author":"Roberts KL","year":"2015","unstructured":"KL Roberts, B Manicassamy, RA Lamb, Influenza A virus uses intercellular connections to spread to neighboring cells. J Virol 89, 1537\u20131549 (2015).","journal-title":"J Virol"},{"key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrmicro1972","article-title":"Avoiding the void: Cell-to-cell spread of human viruses","volume":"6","author":"Sattentau Q","year":"2008","unstructured":"Q Sattentau, Avoiding the void: Cell-to-cell spread of human viruses. Nat Rev Microbiol 6, 815\u2013826 (2008).","journal-title":"Nat Rev Microbiol"},{"key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1111\/j.1558-5646.2012.01687.x","article-title":"Influence of viral replication mechanisms on within-host evolutionary dynamics","volume":"66","author":"Loverdo C","year":"2012","unstructured":"C Loverdo, M Park, SJ Schreiber, JO Lloyd-Smith, Influence of viral replication mechanisms on within-host evolutionary dynamics. Evolution 66, 3462\u20133471 (2012).","journal-title":"Evolution"},{"key":"e_1_3_4_63_2","doi-asserted-by":"crossref","first-page":"e1002744","DOI":"10.1371\/journal.pcbi.1002744","article-title":"Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors","volume":"8","author":"Ke R","year":"2012","unstructured":"R Ke, JO Lloyd-Smith, Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors. PLoS Comput Biol 8, e1002744 (2012).","journal-title":"PLoS Comput Biol"},{"key":"e_1_3_4_64_2","volume-title":"Virus Dynamics","author":"Nowak MA","year":"2001","unstructured":"MA Nowak, RM May Virus Dynamics (Oxford Univ Press, 1st Ed, Oxford, 2001).","edition":"1"},{"key":"e_1_3_4_65_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/978-1-62703-050-2_21","article-title":"Mechanism-based pharmacodynamic modeling","volume":"929","author":"Felmlee MA","year":"2012","unstructured":"MA Felmlee, ME Morris, DE Mager, Mechanism-based pharmacodynamic modeling. Methods Mol Biol 929, 583\u2013600 (2012).","journal-title":"Methods Mol Biol"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1805267115","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1805267115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T13:42:46Z","timestamp":1654609366000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1805267115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":65,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2018,7,24]]}},"alternative-id":["10.1073\/pnas.1805267115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1805267115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"2018-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}